|Bid||37.10 x 1400|
|Ask||37.60 x 800|
|Day's Range||35.10 - 37.76|
|52 Week Range||2.20 - 41.65|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.25|
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.
"This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . In the daily Japanese candlestick chart of PACB, below, we can see that the shares corrected modestly after our Dec. 9 review and subsequently rallied to the $39 price target. This chart shows that prices are above the rising 50-day moving average line and trade at more than three times the level of the rising 200-day moving average line.
Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.